A carregar...

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

BACKGROUND: BRAF inhibitors are effective anticancer agents in BRAF-mutated melanomas. By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma cells are less sensitive to BRAF inhibitors due to activ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell Int
Main Authors: Notarangelo, Tiziana, Sisinni, Lorenza, Condelli, Valentina, Landriscina, Matteo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628448/
https://ncbi.nlm.nih.gov/pubmed/29033690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-017-0457-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!